Repurposing Generic (ReGen) Drugs Evidence Package Challenge
The Repurposing Generic (ReGen) Drugs Evidence Package Challenge from NIH Challenges seeks strong scientific evidence for generic drugs as affordable treatments for costly diseases.
Funder: NIH Challenges
Due Dates: January 15, 2027: Registration deadline | March 26, 2027: Evidence package submissions due
Funding Amounts: Up to $4,000,000 total; up to 40 prizes of $100,000 each for winning evidence packages.
Summary: NIH seeks evidence-based proposals to identify generic drugs for repurposing as affordable treatments for high-cost health conditions.
Description
The Repurposing Generic (ReGen) Drugs Evidence Package Challenge, led by the NIH National Center for Advancing Translational Sciences (NCATS), is a national prize competition seeking comprehensive evidence packages for generic drugs that could be repurposed to address high-cost health conditions. The goal is to identify and prioritize generic drug-disease pairs with promising efficacy signals—supported by clinical or real-world data—that can inform regulatory updates, expanded insurance coverage, and clinical adoption. This initiative targets conditions such as Alzheimer's disease, cancer, diabetes, cardiovascular and mental health disorders, and more, aiming to lower healthcare costs and improve patient outcomes by leveraging the untapped potential of off-patent, low-cost medications.
